Meta-Analysis of Efficacy and Safety of Intravenous Iron in Patients With Iron Deficiency and Heart Failure With Reduced Ejection Fraction.
Publication/Presentation Date
7-8-2023
Abstract
Iron deficiency is an independent risk factor for heart failure (HF) exacerbation. We aim to study the safety and efficacy of intravenous (IV) iron therapy in patients with HF with reduced ejection fraction (HFrEF). A literature search was conducted on MEDLINE (Embase and PubMed) using a systematic search strategy by PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) until October 2022. CRAN-R software (The R Foundation for Statistical Computing, Vienna, Austria) was used for statistical analysis. The quality assessment was performed using the Cochrane Risk of Bias and Newcastle-Ottawa Scale. We included 12 studies with a total of 4,376 patients (IV iron n = 1,985 [45.3%]; standard of care [SOC] n = 2,391 [54.6%]). The mean age was 70.37 ± 8.14 years and 71.75 ± 7.01 years in the IV iron and SOC groups, respectively. There was no significant difference in all-cause mortality and cardiovascular mortality (risk ratio [RR] 0.88, 95% confidence interval [CI] 0.74 to 1.04, p
Volume
202
First Page
119
Last Page
130
ISSN
1879-1913
Published In/Presented At
Hamza, M., Sattar, Y., Manasrah, N., Patel, N. N., Rashdi, A., Khanal, R., Naveed, H., Zafar, M., Khan, A. M., Alharbi, A., Aamir, M., Gonuguntla, K., Raina, S., & Balla, S. (2023). Meta-Analysis of Efficacy and Safety of Intravenous Iron in Patients With Iron Deficiency and Heart Failure With Reduced Ejection Fraction. The American journal of cardiology, 202, 119–130. Advance online publication. https://doi.org/10.1016/j.amjcard.2023.06.066
Disciplines
Medicine and Health Sciences
PubMedID
37429060
Department(s)
Department of Medicine, Cardiology Division, Department of Medicine Fellows and Residents, Fellows and Residents
Document Type
Article